Oral theophylline for chronic obstructive pulmonary disease.

作者: Felix SF Ram , Paul Jones , Jose Jardim , Aldemar A Castro , Álvaro N Atallah

DOI: 10.1002/14651858.CD003902

关键词:

摘要: Background Oral theophylline has, for many years, been used as a bronchodilator in patients with COPD. Despite the introduction of new drugs, and its narrow therapeutic index, is still recommended COPD treatment. Objectives To determine effectiveness oral when compared to placebo stable COPD. Search methods We searched Cochrane Airways Group trial register Central Register Controlled Trials Clinical Registers were searched. Selection criteria All studies randomised controlled trials (RCTs). Data collection analysis Two reviewers independently abstracted data asessed methodological quality. Main results Twenty RCTs met inclusion criteria. Concomitant therapy varied from none any other plus corticosteroid (oral inhaled). The following outcomes significantly different placebo. Forced expiratory volume one second (FEV1) improved treatment: Weighted Mean Difference (WMD) 100 ml; 95% Confidence Interval (CI) 40 160 ml. Similarly forced vital capacity (FVC): WMD 210 ml 95%CI 320. Two reported an improvement maximum oxygen consumption (VO2 max); 195 ml/min, 113 278. At rest, arterial tension at rest (PaO2) carbon dioxide (PaCO2) both treatment (WMD 3.2 mm Hg; 1.2 5.1, -2.4 -3.5 -1.2, respectively). Walking distance tests did not improve (four studies, Standardised 0.30, -0.01 0.62), neither Visual Analogue Score breathlessness two small 3.6, -4.6 11.8). Relative Risk (RR) nausea was greater (RR 7.7; 1.5 39.9). However, patients' preference than that 2.27; 1.26 4.11). Very few participants withdrew these reason. Authors' conclusions Theophylline has modest effect on FEV1 FVC slightly improves blood gas tensions moderate severe These benefits seen receiving variety concomitant therapies. Improvement exercise performance depended method testing. There very low dropout rate could be included this review, which suggests recruited may have known by investigators tolerant . This limit generalisability studies.

参考文章(127)
JosephH Levine, JohnR Michael, Thomas Guarnieri, MULTIFOCAL ATRIAL TACHYCARDIA: A TOXIC EFFECT OF THEOPHYLLINE The Lancet. ,vol. 325, pp. 12- 14 ,(1985) , 10.1016/S0140-6736(85)90964-X
Gabriele Di Lorenzo, Giuseppina Morici, Agata Drago, Maria Esposito Pellitteri, Pasquale Mansueto, Marcello Melluso, Francesco Norrito, Lisa Squassante, Adriano Fasolo, SLMT02 Italian Study Group, Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease Clinical Therapeutics. ,vol. 20, pp. 1130- 1148 ,(1998) , 10.1016/S0149-2918(98)80109-4
Takahiko Horiguchi, Soichi Tachikawa, Junichi Kasahara, Masashi Doi, Mamoru Shiga, Junichi Miyazaki, Yasushi Sasaki, Masahiro Hirose, Moritaka Imazu, Suppression of airway inflammation by theophylline in adult bronchial asthma Respiration. ,vol. 66, pp. 124- 127 ,(1999) , 10.1159/000029353
C PERSSON, Overview of effects of theophylline The Journal of Allergy and Clinical Immunology. ,vol. 78, pp. 780- 787 ,(1986) , 10.1016/0091-6749(86)90061-8
H. Folgering, C. v. Herwaarden, Exercise Limitations in Patients with Pulmonary Diseases International Journal of Sports Medicine. ,vol. 15, pp. 107- 111 ,(1994) , 10.1055/S-2007-1021029
Kumar Ashutosh, Mohammad Sedat, Jody Fragale-Jackson, Effects of Theophylline on Respiratory Drive in Patients with Chronic Obstructive Pulmonary Disease The Journal of Clinical Pharmacology. ,vol. 37, pp. 1100- 1107 ,(1997) , 10.1002/J.1552-4604.1997.TB04293.X
Gordon H Guyatt, Marie Townsend, Jana L Keller, Joel Singer, SHOULD STUDY SUBJECTS SEE THEIR PREVIOUS RESPONSES: DATA FROM A RANDOMIZED CONTROL TRIAL Journal of Clinical Epidemiology. ,vol. 42, pp. 913- 920 ,(1989) , 10.1016/0895-4356(89)90105-4